Document is current
Any future updates will be listed below
-
Authors
Milne, Richard J. https://orcid.org/0000-0002-9410-1667
Schousboe, Carsten https://orcid.org/0000-0002-0167-9444
Campbell, Julie A. https://orcid.org/0000-0002-1820-6758
Mottershead, John https://orcid.org/0000-0001-5638-8786
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
University of Tasmania
- License Information
-
More Information
Article History
Accepted: 18 March 2025
First Online: 7 May 2025
Declarations
:
: This study was funded by a grant from Roche Products (New Zealand) Ltd to Multiple Sclerosis New Zealand (MSNZ). Roche NZ reviewed an early draft of the manuscript but neither MSNZ nor Roche had any role in the analysis or interpretation of results or the decision to submit the manuscript for publication. CS is employed as a health economist by F. Hoffmann-La Roche Ltd (Roche) and owns shares in the company. None of the other authors have any relevant financial interest. RM is an Editorial Board Member of PharmacoEconomics. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: Open Access funding enabled and organized by CAUL and its Member Institutions. RM was funded by a grant from Roche Products (NZ) Ltd to Multiple Sclerosis NZ. He has received conference support from Roche Products (NZ) Ltd. CS is an employee of Roche Singapore Pte and was previously an employee of Pharmac. JC has received funding from Multiple Sclerosis Australia. JM has received honoraria from Roche Products (NZ) Ltd.
: Model development by RM and CS; review of cost data by JC; analyses by RM and CS; review of clinical information by JM; manuscript development and final approval by all authors.
: The Markov model can be obtained from the lead author on request
